Story
Hims & Hers Stock Slips on Pre-Earnings Caution and Analyst Concerns

Shares of Hims & Hers Health, Inc. (NYSE: HIMS) declined in pre-market trading Monday as investors reduced their positions ahead of the company's second-quarter 2026 earnings report, which is scheduled for release after the market close.
The stock fell 1.5% to $31.12 in pre-open activity, giving back a portion of the 6.5% gain it recorded in the prior session in a move attributed to pre-earnings profit-taking.
Analyst Caution and Slowing Growth Signals
Adding to the cautious tone, Truist Securities reiterated a Hold rating on Hims & Hers with a $27 price target, a significant discount to the stock's recent trading levels. The firm's analysis pointed to potential headwinds in a key growth area for the telehealth company.
According to Truist's proprietary card data, billings for GLP-1 weight-loss drugs declined by 1% month-over-month in July. This marks a notable slowdown after a robust 32% month-over-month jump in June, raising questions among investors about the sustainability of that momentum.
Earnings Expectations and Legal Headwinds
AdAnalysts broadly expect Hims & Hers to report a net loss for the second quarter, a reversal from the profit it posted in the same period a year ago.
- Earnings Per Share (EPS): Consensus estimates forecast a loss of approximately $0.05 per share, compared to a profit of $0.17 per share in Q2 2025.
- Revenue: The consensus revenue estimate is near $730 million.
- Implied Volatility: Options markets have priced in a potential post-earnings stock swing of roughly 14.5% in either direction, according to Investing.com.
The company also continues to face legal and regulatory scrutiny. In late July, the Federal Trade Commission (FTC) filed a lawsuit alleging Hims & Hers shared sensitive user health data with third-party advertising platforms. This legal overhang, along with separate investigations by law firms over alleged securities violations, has weighed on investor sentiment.
The upcoming earnings report and management's outlook will be a critical test for the stock's direction, balancing bullish long-term views on its product pipeline against these near-term concerns.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.